<DOC>
	<DOCNO>NCT02621970</DOCNO>
	<brief_summary>The investigator aim evaluate survival benefit triple combination induction , concurrent aduvant chemotherapy versus concurrent chemotherapy alone high risk locoregionally advanced nasopharyngeal carcinoma treat intensity-modulated radiotherapy .</brief_summary>
	<brief_title>Effect Triple Combination Induction , Concurrent Adjuvant Chemotherapy High Risk Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>All eligible patient receive intensity-modulated radiotherapy ( IMRT ) total dose 68 70 Gy 33 fraction primary tumor . Patients experimental arm receive triple therapy induction , concurrent adjuvant chemotherapy . Induction chemotherapy consist docetaxel 75 mg/m² , D1 cisplatin 25 mg/m² , D1-3 every 3 week 2 cycle . Concurrent chemotherapy experimental arm consist cisplatin 25 mg/m² , D1-3 every 3 week Xeloda 2000mg/m² , D1-14 3 cycle . Adjuvant chemotherapy consist Xeloda 2500mg/m² , D1-14 2 cycle . Concurrent chemotherapy control arm consist cisplatin 100 mg/m² , D1 every 3 week 3 cycles.The primary endpoint failure-free survival ( FFS ) . Secondary end point include overall survival ( OS ) , locoregional relapse-free survival ( LRFS ) , distant metastasis-free survival ( DMFS ) incidence grade 3 high acute toxicity . All efficacy analysis conduct intention-to-treat population , safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Newly histologically confirm nonkeratinizing ( WHO 1991 ) nasopharyngeal carcinoma . Tumor stag T4N03M0 T13N3M0 ( 2010 UICC/AJCC stag system ) . Pretreatment EBV DNA ≥ 4000 copies/mL . Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4×10E9/L , hemoglobin ≥ 110g/L platelet count ≥ 100×10E9/L . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) bilirubin ≤ 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min creatinine ≤ 1.5×ULN . Patients must give write informed consent . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous radiotherapy ( except nonmelanomatous skin cancer outside intend radiotherapy volume ) . Prior radiotherapy , chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance . Dihydropyrimidine dehydrogenase deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>